Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels


Protalix, Chiesi Global Announce Topline Results From The


RTTNews | Jun 2, 2021 08:02AM EDT

08:01 Wednesday, June 2, 2021 (RTTNews.com) - Protalix BioTherapeutics, Inc. (PLX) and Chiesi Global Rare Diseases, a unit of Chiesi Farmaceutici S.p.A., reported positive initial top line results from the Phase 3 study of pegunigalsidase alfa (PRX-102), dubbed Balance, for the proposed treatment of Fabry disease. The Balance study of PRX-102 in Fabry patients with impaired renal function evaluates the safety and efficacy of 1 mg/kg of PRX-102 dosed every two weeks compared to agalsidase beta (Fabrazyme).

The primary endpoint of the interim analysis is the comparison of mean annualized changes of the eGFR (CKD-EPI) after completion of at least 12 months of treatment between the two treatment arms.

The initial top-line results show that the lower boundary of the confidence interval for the mean difference between the two treatments was below the non-inferiority margin pre-specified for this interim analysis in the ITT analysis set and above such limit in the PP analysis set.

Based on the 12-month data from the Balance study, along with positive data from Phase 3 Bright and Bridge studies, Protalix and Chiesi plans to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA).

Protalix and Chiesi also plan to submit a Type-A meeting request with the FDA to discuss the path for approval of PRX-102.

Read the original article on RTTNews ( https://www.rttnews.com/3199332/protalix-chiesi-global-announce-topline-results-from-the-interim-analysis-of-balance-study.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC